A unique bacterial profile in the guts of patients with pulmonary arterial hypertension (PAH) may contribute to the disease and help predict it, a study found. The identification of specific microorganisms may lead to earlier, less invasive diagnoses, as well as new avenues for treatment. The study,…
News
Starting a 501(c)(3) tax-exempt nonprofit isn’t easy, but the National Organization for Rare Disorders gave a few tips for those  looking to begin the complex process in its Feb. 20 webinar. William Whitman…
The ATS Foundation Research Program and Pulmonary Hypertension Association have announced the 2019 recipients of their partner grants, totaling $210,000, for young researchers dedicated to scientific discovery and better patient care in the field of pulmonary hypertension. An $80,000 Foundation Partner grant was awarded to Rahul Kumar, PhD, a…
Use of Bellerophon Therapeutics’ INOpulse device — which provides nitric oxide to the lungs — significantly improved parameters related to blood flow in the lungs in people with pulmonary hypertension associated with pulmonary fibrosis (PH-PF), top-line data from…
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
Oral delivery of two proteins produced on lettuce leaves and involved in blood vessel health eased pulmonary hypertension and heart abnormalities in a rat model of pulmonary arterial hypertension (PAH). These results point to this plant-based approach as a potentially safe, inexpensive, shelf-stable treatment for PAH. Further studies…
Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, “Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension,” was published in the journal CHEST. The study details the case of…
The buildup in the lungs and plasma of oxidized low-density lipoproteins, or LDLs — one of the major vehicles for the transport of cholesterol and other types of fatty molecules in the body — is associated with the progression of pulmonary hypertension (PH), a study reports. However,…
Aria CV‘s medical device for treating pulmonary hypertension (PH) has been given a Breakthrough Device designation by the United States Food and Drug Administration (FDA). The Aria CV PH System is designed to reduce the symptoms associated with PH — a condition that develops due to…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
Switching from injectable treprostinil or epoprostenol to a combination therapy including inhaled treprostinil appears to be safe, well tolerated, and effective for a select group of patients with clinically stable pulmonary arterial hypertension (PAH), a study suggests. The study, “Ambulatory Transition from Parenteral Prostanoid…
The biopharmaceutical PhaseBio announced positive results from a case study involving a patient with pulmonary arterial hypertension (PAH) who received treatment with PB1046, a new therapy using the company’s proprietary technology platform. PB1046…
